Bellicum Pharmaceuticals, Inc. BPXA.F Stock
Bellicum Pharmaceuticals, Inc. Price Chart
Bellicum Pharmaceuticals, Inc. BPXA.F Financial and Trading Overview
| Bellicum Pharmaceuticals, Inc. stock price | 0.16 EUR |
| Previous Close | 0.31 EUR |
| Open | 0.35 EUR |
| Bid | 0.3 EUR x N/A |
| Ask | 0.34 EUR x N/A |
| Day's Range | 0.35 - 0.36 EUR |
| 52 Week Range | 0.11 - 1.45 EUR |
| Volume | 1K EUR |
| Avg. Volume | 116 EUR |
| Market Cap | 4.19M EUR |
| Beta (5Y Monthly) | 1.512676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
BPXA.F Valuation Measures
| Enterprise Value | 10.07M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.7772858 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 6.676 |
| Enterprise Value/EBITDA | -0.339 |
Trading Information
Bellicum Pharmaceuticals, Inc. Stock Price History
| Beta (5Y Monthly) | 1.512676 |
| 52-Week Change | -70.85% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.45 EUR |
| 52 Week Low | 0.11 EUR |
| 50-Day Moving Average | 0.39 EUR |
| 200-Day Moving Average | 0.84 EUR |
BPXA.F Share Statistics
| Avg. Volume (3 month) | 116 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 9.5M |
| Float | 8.42M |
| Short Ratio | N/A |
| % Held by Insiders | 4.19% |
| % Held by Institutions | 29.30% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1968.63% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.14% |
| Return on Equity (ttm) | -106.13% |
Income Statement
| Revenue (ttm) | 1.51M EUR |
| Revenue Per Share (ttm) | 0.05 EUR |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -29678000 EUR |
| Net Income Avi to Common (ttm) | -25477000 EUR |
| Diluted EPS (ttm) | -0.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.4M EUR |
| Total Cash Per Share (mrq) | 1.62 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.655 |
| Book Value Per Share (mrq) | -1.108 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25836000 EUR |
| Levered Free Cash Flow (ttm) | -17431376 EUR |
Profile of Bellicum Pharmaceuticals, Inc.
| Country | Germany |
| State | TX |
| City | Houston |
| Address | 3730 Kirby Drive |
| ZIP | 77098 |
| Phone | 281 454 3424 |
| Website | https://www.bellicum.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 13 |
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Q&A For Bellicum Pharmaceuticals, Inc. Stock
What is a current BPXA.F stock price?
Bellicum Pharmaceuticals, Inc. BPXA.F stock price today per share is 0.16 EUR.
How to purchase Bellicum Pharmaceuticals, Inc. stock?
You can buy BPXA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bellicum Pharmaceuticals, Inc.?
The stock symbol or ticker of Bellicum Pharmaceuticals, Inc. is BPXA.F.
Which industry does the Bellicum Pharmaceuticals, Inc. company belong to?
The Bellicum Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Bellicum Pharmaceuticals, Inc. have in circulation?
The max supply of Bellicum Pharmaceuticals, Inc. shares is 9.5M.
What is Bellicum Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Bellicum Pharmaceuticals, Inc. PE Ratio is now.
What was Bellicum Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Bellicum Pharmaceuticals, Inc. EPS is -0.66 EUR over the trailing 12 months.
Which sector does the Bellicum Pharmaceuticals, Inc. company belong to?
The Bellicum Pharmaceuticals, Inc. sector is Healthcare.